Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Boeri miRNA signature of diagnosis of lung cancer

Boeri miRNA signature of diagnosis of lung cancer

Basics

Attributes

QA State: Curated
Short Name:

miRNA expression analyses in plasma samples collected 1â€â€Å"2 y before the onset of disease, at the time of CT detection and in disease-free smokers enrolled in the screening trial, resulted in the generation of miRNA signatures with strong predictive, diagnostic, and prognostic potential (area under the ROC curve ≥ 0.85). The signature of diagnosis of lung cancer is comprised of 16 ratios composed from 13 miRNAs: 21, 92a, 140-3p, 17, 106a, 140-5p, 660, 19b, 451, 30c, 15b, 28-3p, 486-5p.

Panel Details

No member markers defined for this panel.

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: One
QA State: Curated

Overall, these findings strengthen the observation that circulating miRNA in plasma is detectable well before clinical disease detection by spiral CT, indicating the possibility to select high-risk groups on the basis of miRNA profiling.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement